Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00421018

Enrollment

187

Registered

2007-01-11

Start date

2006-11-30

Completion date

2010-04-30

Last updated

2012-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Asthma

Keywords

Asthma, Allergy, Cytokines, Glucocorticoids, Inflammation, Nitric Oxide (NO), Quality of Life, Self-Rated Health, Stress

Brief summary

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

Interventions

DRUGSingle corticosteroid inhalers and Singulair

Treatment steps according to preset algorithm

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Age 18-64 * Clinical diagnosis of Asthma * Glucocorticoid treatment \> 6 months. * Verified Allergy * Read and speak Swedish

Exclusion criteria

* Smoking * Current regular treatment with long-acting beta2-agonist * Treatment with Singulair only or in combination with glucocorticoids * Taking part in other research study * Pregnancy or breast-feeding * Unstable Asthma

Design outcomes

Primary

Measure	Time frame
Mini-AQLQ (Asthma-Related Quality of Life)	1 year

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026